Research Lab Applies to Import Ibogaine and Marijuana
Published Date: 6/17/2026
Notice
Summary
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Importer application could supply researchers
Scottsdale Research Institute applied on May 19, 2026 to register as an importer of Schedule I bulk active pharmaceutical ingredients for ibogaine (drug code 7260), marihuana (7360), and 3,4‑Methylenedioxymethamphetamine/MDMA (7405). The company says it plans to import these bulk APIs to support clinical research by Schedule I registrants.
Synthetic cannabidiol imported under marijuana code
For the marihuana drug code (7360), Scottsdale Research Institute plans specifically to import a synthetic cannabidiol as a bulk active pharmaceutical ingredient. That import would be intended to support clinical research by Schedule I registrants.
Registration excludes finished drug imports for sale
The notice states that approval of this importer registration will not authorize importation of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. The registrant’s authorization is limited to the activities allowed under 21 U.S.C. 952(a)(2).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
Previous / Next Documents
Previous: 2026-12138 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc., also known as PCI Pharma Services, wants to become an official importer of certain controlled substances. This means they’ll be allowed to bring in specific drugs under government rules. People who make or use these drugs can share their thoughts or ask for a hearing by July 17, 2026, so keep an eye on that deadline!
Next: 2026-12141 — Importer of Controlled Substances Application: Veranova, L.P.
Veranova, L.P. wants to become an official importer of certain controlled substances like coca leaves and opium. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could shake up the drug import scene and might affect how these substances are handled and tracked.